Latest Conference Articles

January 15th 2021, 4:55pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - Findings from an analysis determined that stage 4 gastrointestinal stromal tumors were rare and led to hepatic metastases, although overall survival was up to 51% at 5 years.

January 15th 2021, 4:40pm

January 15, 2021 - Pembrolizumab (Keytruda) in combination with capecitabine and bevacizumab (Avastin) was found to show encouraging tolerability when used in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC), according to data from a phase 2 trial (NCT03396926) presented during the 2020 Gastrointestinal Cancers Symposium.

December 14th 2020, 10:30pm

PER® International Congress on Immunotherapies in Cancer: Focus on Practice-Changing Application

The emergence of checkpoint inhibitors has transformed the second-line treatment of patients with metastatic bladder cancer. However, questions regarding the utility of immunotherapy in the frontline setting remain unanswered, leaving chemotherapy as the standard-of-care option.

December 14th 2020, 9:33pm

PER® International Congress on Immunotherapies in Cancer: Focus on Practice-Changing Application

Joshua Brody, MD, discusses the role of immunotherapy in Hodgkin lymphoma.

December 14th 2020, 9:30pm

PER® International Congress on Immunotherapies in Cancer: Focus on Practice-Changing Application

Jeffrey S. Weber, MD, PhD, discusses the toxicities associated with immunotherapy in lung cancer.

December 14th 2020, 9:00pm

PER® International Congress on Immunotherapies in Cancer: Focus on Practice-Changing Application

Checkpoint inhibitors have failed to improve progression-free survival and overall survival as second-line therapy and maintenance therapy in small cell lung cancer, but this class of agents continue to show encouraging activity worthy of a paradigm shift up front.

December 14th 2020, 7:35pm

PER® International Congress on Immunotherapies in Cancer: Focus on Practice-Changing Application

Mario Sznol, MD, discusses the critical importance of being aware of the immune-related toxicities that could arise when treating patients with cancer, along with the best ways to manage them.

December 14th 2020, 4:35pm

San Antonio Breast Cancer Symposium

December 14, 2020 - The combination of neratinib and capecitabine showed a 34% reduction in the risk of disease progression or death compared with lapatinib and capecitabine in patients with HER2-positive breast cancer who had central nervous system metastases at baseline.

December 12th 2020, 1:18am

San Antonio Breast Cancer Symposium

Erika P. Hamilton, MD, discusses the mechanism of action of OP-1250 in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

December 12th 2020, 1:06am

San Antonio Breast Cancer Symposium

Nadia Harbeck, MD, PhD, discusses Ki-67 as a biomarker for identifying patients with high-risk early breast cancer who received treatment on the monarchE trial.

December 12th 2020, 12:29am

San Antonio Breast Cancer Symposium

December 11, 2020 - Tucatinib in combination with trastuzumab and capecitabine significantly prolonged the time to deterioration of health-related quality of life in patients with HER2- positive metastatic breast cancer with brain metastases.

December 11th 2020, 11:34pm

San Antonio Breast Cancer Symposium

December 11, 2020 - The addition of 1 year of palbociclib to endocrine therapy failed to improve invasive disease-free survival in patients with hormone receptor–positive, HER2-negative breast cancer who are at high risk of relapse following neoadjuvant chemotherapy.

December 11th 2020, 10:00pm

San Antonio Breast Cancer Symposium

The clinical tool RSClin™, which integrates the 21-gene expression assay and clinical pathologic features, was shown to provide more prognostic information than the 21-gene recurrence score or clinical pathologic features alone and a more precise prediction of absolute chemotherapy benefit in node-negative early breast cancer.

December 11th 2020, 9:44pm

San Antonio Breast Cancer Symposium

December 11, 2020 - Gastrointestinal adverse events that occurred in patients with metastatic breast cancer who were treated with oral paclitaxel and encequidar can be managed by the use of 5- HT3 inhibitors and early intervention with loperamide.

December 11th 2020, 9:33pm

San Antonio Breast Cancer Symposium

December 11, 2020 - Sacituzumab govitecan increased response rates and improved progression-free survival vs chemotherapy in patients with metastatic triple-negative breast cancer with stable brain metastases, although no overall survival improvement was observed.

December 11th 2020, 8:41pm

San Antonio Breast Cancer Symposium

December 11, 2020 - The presence of circulating tumor DNA following neoadjuvant chemotherapy with or without pembrolizumab was a biomarker for response and distant recurrence-free survival in patients with high-risk early-stage breast cancer.

December 11th 2020, 6:39pm

San Antonio Breast Cancer Symposium

December 11, 2020 - Patients with human epidermal growth factor receptor 2-negative, hormone receptor-positive metastatic breast cancer who were treated with tesetaxel and a reduced dose of capecitabine experienced improvements in progression-free survival compared with those treated with the FDA-approved dose of capecitabine alone.

December 11th 2020, 4:40pm

San Antonio Breast Cancer Symposium

December 11, 2020 - The combination of plinabulin and pegfilgrastim was 53% more effective in reducing the incidence of profound neutropenia compared with pegfilgrastim alone in patients undergoing chemotherapy, according to full findings of the phase 3 PROTECTIVE-2 trial.

December 11th 2020, 3:30pm

San Antonio Breast Cancer Symposium

December 11, 2020 - Use of a novel HER2 quantitative continuous score was better able to provide an objective and quantitative assessment of HER2 expression to identify patients who are most likely to respond to fam-trastuzumab deruxtecan-nxki.

December 11th 2020, 12:57am

San Antonio Breast Cancer Symposium

December 10, 2020 - The GP2 immunotherapy plus granulocyte-macrophage colony-stimulating factor demonstrated potent responses and a 100% disease-free survival in patients with HER2/neu 3–positive disease who received adjuvant trastuzumab.